The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®
Mar 18, 2025•about 1 year ago
Contract Type
contract
PrincetonBiotechnologyPharmaceutical
Description
ANI Pharmaceuticals, Inc. has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC (SWK) on worldwide net revenues of ILUVIEN and YUTIQ for a one-time payment of $17.25 million. This reflects ANI's commitment to strengthening their Retina portfolio and maximizing the long-term value of ILUVIEN and YUTIQ. By eliminating this royalty obligation, ANI has enhanced its financial flexibility and ability to accelerate growth.
Company Information
Company
ANI Pharmaceuticals
Location
Princeton, New Jersey, United States
About
ANI Pharmaceuticals, Inc. is a global pharmaceutical company with a strategic focus on expanding its Rare Disease business. The company aims to deliver substantial shareholder value creation through high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and substantial growth thereafter. ANI is dedicated to serving patients and improving lives through its diversified portfolio of commercial assets and global infrastructure.
PrincetonBiotechnologyPharmaceutical